Observational Study of Tamsulosin in Patients With Benign Prostatic Hyperplasia

Boehringer Ingelheim

Status: Completed

Conditions: Prostatic Hyperplasia

Treatments: Drug: Tamsulosin

Study type: Observational

Funder types: Industry

Identifiers

NCT02245555

527.73

Details and patient eligibility

About

Study to describe Tamsulosin prescription characteristics in a representative population of patients on treatment for benign prostatic hyperplasia

Enrollment: 1,060 patients

Sex: Male

Ages: 21+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients older than 21 years old diagnosed with benign prostatic hyperplasia (BPH), who require pharmacological treatment to relieve symptoms and improve their quality of life, according to physician's judgment. The study will include naïve patients and patients not responding to previous therapy who receive Secotex as alternative or complementary treatment. The decision to treat a patient with Tamsulosin must be based on the best standard accepted in the clinical practice and must be carried out following Secotex (Tamsulosin) prescription information

Exclusion criteria

• Patients with known hypersensitivity to Tamsulosin or any of its ingredients, history of orthostatic hypotension or severe liver failure, or with any missing data required to complete the questionnaire are excluded

Trial design

1,060 participants in 1 patient group

Patients with benign prostatic hyperplasia

Treatment:

Drug: Tamsulosin